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ABSTRACT

An abstract of the thesis of Xuehui Liu for the Master of Science in Biology presented
April 11, 1994.

Title: Studies on the Role of Cellular Factor, YYl, in Herpes Simplex Virus Type 1
Late Gene Expression

The herpes simplex virus 1 (HSVl) VP5 gene codes for the major viral
capsid protein. Understanding of the mechanism of how the VP5 gene is regulated
in host cells will help us to understand the molecular action of the HSV 1 life cycle
and its interplay with the host cell gene expression machinery (transcription and
translation). This may ultimately provide scientific bases for both better prevention
and cure of HSV 1 caused diseases. Previous work from Dr. Robert L. Millette' s
laboratory has indicated that a 164 base pair region of the VP5 promoter gene could
activate the transcription of an attached reporter gene (bacteria CAT gene).
Furthermore, a 12 bp (GGCCATCTTGAA) cis-acting element situated within the
164 bp promoter region was required for the promoter activity. To understand the
function of this cis-element in the regulation of VP5 transcription and to identify the

trans-acting factors interacting with this element, gel mobility shift assays were first
carried out using the fragment containing the 12 bp site as the probe. A cellular
,

factor, YY 1, was found to bind to this site in a sequence specific manner. Based on

2

the oligonucleotide competition assays, partial protease digestions, and antibody
supershift assays, it became clear that two cellular factors bound to the VP5
promoter. These were related, if not identical, to the previously identified Yin-Yang1 factor (YY 1), and transcription factor the SPl. Site-directed mutagenesis studies
indicated that these two factors bind to distinct sites on the 164 bp fragment. Point
mutations studies on the 12 bp YYl binding site demonstrated that seven of the 12
bp were required for YY 1-DNA complex formation and the first four bp in the 12 bp
were very important for VP5 gene regulation. Also, it was found that YY 1 performs
both positive and negative regulator function in VP5 gene regulation. In conclusion,
two cellular transcription factors, YY 1 and SPl, play a major role in VP5 gene
expression.
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CHAPTER I
INTRODUCTION
1. General
Virology as a new individual science is developing very fast. In 1892, Russian
chemist Iwanovski discovered the tobacco mosaic virus (24) ~ this was the first human
observation in the field of virology. Viruses are the smallest infectious bioorganisms
known in the world. Their size comparison with the bacterium Escherichia coli is
shown in Figure 1.
One century has passed since the tobacco virus was discovered, and the science
of virology has expanded more and more. Transmission by a cell-free filtrate was
demonstrated, for foot-and-mouth disease in 1898, for chicken sarcoma in 1911, and
viruses infecting bacteria were discovered in 1917 (11, 24). Now, the molecular
virology is becoming more and more important in both the basic science research and
the clinical application.
Even though viruses are extremely small, they are of great of importance in
human disease. Many acute diseases are due to viral infection (49). In some virus
infections, not only the incidence of the disease, but also the mortality is very high. In
recent years, viral diseases have resulted many social and economic problems in many
countries. For example, AIDS (Acquired Immunodeficiency Syndrome), caused by the
human immunodeficiency virus (HIV), has taken a heavy toll of lives, and millions of
dollars have been spent on its prevention and keeping those affected alive.
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Fig. 1. Comparative sizes of virions, their nucleic acids,
and bacteria. The profiles and the lengths of the DNA
molecules are all reproduced on the same scale.
( Dulbecco. 1988. )
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The herpesviruses are a very big family named for those members responsible
for two common diseases of human: herpes simplex virus (fever blister) and herpes
zoster virus (chickenpox and shingles ). The herpesviruses have another characteristic,
the ability to produce latent and recurrent infections. Even though the mechanism
involved is not very clear, this aspect of herpes infection is very important in both
clinical and basic science. Beside human infections, herpesviruses infections have also
been found in other species, for example, B virus of monkeys (which may infect man
accidentally), pseudorabies virus of pigs, virus III of rabbits, cytomegaloviruses of
animals, and oncogenic viruses that produce lymphoproliferative malignancies in
chickens and monkeys (49).

2. The family of human herpesvirus

The herpesvirus family has almost 100 members that have been at least partially
characterized. Among them, seven herpesviruses have been isolated so far from
humans. They are: herpes simplex virus type 1 (HSVl), herpes simplex virus type 2
(HSV2), humancytomegalo virus (HCMV), varicella-zoster virus (VZV), Epstein-Barr
virus (EBV), human herpesvirus 6 (HHV6), and human herpesvirus 7 (HHV7). All of
the human herpes viruses have the same basic architecture which includes four main
parts: (a) the core comprised of DNA with some proteins, (b) the viral capsid which is
about lOOµm in diameter and comprised of 162 capsomeres, (c) the tegument, the
structure located between capsid protein and envelope, and (d) the envelope derived
from the cells inner nuclear membrane with inserted viral glycoproteins (Fig.2) (11).
Herpesvirus DNAs are double-stranded and linear in nature. Once the virus
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Fig. 2 The morphology of herpesviruses. A: Schematic representation of the
herpesvirion seen through a cross-section of the envelope with spikes projecting from this
surface. B: An intact negatively stained HSVl virion. C: An HSVI capsid in A. D:
HSVl capsid containing DNA penneated with tuanyl acetate. E, F, G: Electron
micrographs of thin section of HSV 1 virions showing the core cut at different angles
(Roizman 1993).
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infects the cells, linear DNA will become circular after it is released into the infected cell
nuclei. The size of herpesvirus DNAs are approximately 120 to 230 Kilobase pairs
(kbp), and they range from 31 % to 75% in G+C content. Although the DNAs of
different herpesviruses have different gene structure, the DNA at many of them consist
of two covalently linked sequences designed long unit (Ul) and short unit (Us),
comprising 82% and 18% of the genomes pectively (Fig.3). Because of the ability of
the Ul and Us to invert relative each other, many of the herpesvirus genomes have at
least 2, some have 4 equimolar isomers (11).
According to the International Committee on the Taxonomy of Viruses,
herpesviruses are divided into three subfamilies (48 ):

Alpha Herpesvirus (a-Herpesvirus). These infect the cell very rapidly,
and quickly spread to adjacent cells in culture. They usually destroy host cells quickly
and establish latent infections in neurons. This subfamily includes HSVl, HSV2 and

vzv.

Beta Herpesvirus ((3-Herpesvirus). These have a long reproductive cycle
and slowly spread in culture. After infection, the infected cells become enlarged. This
subfamily causes latent infection in secretary glands, lymphoreticular cells, kidneys and
other tissues. Human cytomegalovirus (HCMV) belongs to this subfamily.

Gamma Herpesvirus (y-Herpesvirus).

All these subfamily members

replicate in lymphoblastoid cells, T or B cells. Some can cause lytic infections in some
types of epithelioid and fibroblastic cells. Epstein-Barr virus (EBV) belongs to this
group.
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Fig. 3. Diagrams of the physical structures of genomes of several
viruses of the family Herpesviridae. The genomes are composed of
unique (U) sequences with short (S) or long (L) region. Terminal
repeats (TR) bound the genome, and inverted repeats (IR) bound t
he unique regions.
The rectangles contain reiterated sequences of
more than 1000 base pairs. (Dulbecco.1988. )
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As one of the big families of viruses, herpesviruses can cause many diseases in
human and other animals. Human herpesviruses are clinically very important for human
beings.

The most common diseases resulting from herpesvirus infections are

chickenpox and fever blisters. Over 87% of America people been infected by one or
more herpesviruses ( 49).
Fever blisters or cold sores are a very common disease resulting from HSV 1
infection, the very common area is oral. HSV2 mainly produces genital infections.
Only seroepidemiologic studies can distinguish the differences between HSV 1 and
HSV2. But, usually, the antibodies directed to HSV2 can be tested in the young baby
and the antibodies directed to HSVl can be tested in children less than 10 years old.
Skin and mucosa! surface are the initial or primary infection sites for HSV 1 with the
mouth and lips being the most common places of the infection of HSVl. Manifestations
of the infection can be fever, sore throat, ulcerative and vesicular lesions, edema and so
on. The incubation period ranges from 2 to 12 days. And the duration of clinical illness
is about 2 to 3 weeks (49).
The most common diseases caused from the VZV are chickenpox (varicella) and
shingles ( herpes zoster ). Chickenpox is a ubiquitous, highly contagious, generalized
exanthem that spreads rapidly in a susceptible population and displays marked
seasonality. Shingles ( herpes zoster) occurs usually in older individuals and is
characterized by a painful vesicular eruption generally limited to a single dermatome.
In the herpesvirus family, the most important thing that is different from other
viruses is that herpesviruses can produce both primary and recurrent infections. The
recurrent infections are due to the abilities to establish latency. The primary infections
occur mainly in children, and the recurrent infections in adults. After a primary HSV
infection, the latency can be established very soon in the neurons. This is believed to
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occur without the production of cell death, because the viruses generally do not replicate
in the neurons. For example, the reactivation of HSV can be many caused by exposure
to cold, sunlight, wind, dental procedures, sexual intercourse.

3.

Herpes simplex viruses and their life circle

This research focuses on herpes simplex virus type 1 (HSVl). This virus
causes many different kinds infections in humans. The most common disease caused
by HSV 1 are fever blisters or cold sores as described before. The more severe
manifestations of HSV 1 infections are: (a) disseminated disease to visceral organs, (b)
the severe deep ocular involvement which can lead to blindness, and (c) herpes
encephalitis (49). A unique property of the herpes simplex viruses is their ability to
cause latent infection in neurons. Normally, after first infection, they travel to the
sensory neurons that innervate the region of infection. There they can remain latent in
their host and they can be later reactived to cause lesions at or near the site of initial
infection. Latent virus has been retrieved from the trigeminal, sacral and vagal ganglia
of humans (49). Reinfection with the same strain of HSV can occur by autoinoculation
at a distant site. So, the HSVl can be mechanically transmitted from one site to either
an adjacent site or a distal site (11,48,49).
The replication cycle of HSV 1 has been extensively studied, and it is comprised
of the following steps (Fig.4) (11, 24, 48):
(1). Attachment: All the susceptible cell membranes have the HSVl receptors to

match the antireceptors on the virus surface. When the virus has attached to the cell
surface, the viral envelope fuses with the cell membrane and the nucleocapsid is released

9

into the cytoplasm. This step does not need any energy which depends on the specific
affinity between both cell and virus glycoproteins B, D, H, K, L. Normally, herpes
simplex viruses infect and replicate in epithelial cells and become latent in neuron cells.
(2). Penetration: Herpesviruses penetrate the infected cell by fusion of the viral
envelope and cell plasma membrane. This step rapidly follows attachment . Viral
glycoproteins E (gE), gB and gD perform very important functions in this procedure.
(3). Uncoating: After entering the cell, the viral capsid is transported to the
nuclear pores quickly and then the DNA is released into the nucleus.
(4). Replication. DNA replication, transcription and new capsid assembly occur
in nucleus. Herpes simplex viruses have 72 gene products, 56 open read frames are in
Ul, 12 in Us and 1 each in the repeat regions (Fig.3). All of the viral genes and their
products are divided to 5 groups: a, fl 1, f32, yl and y2 based on the kinetics of the ir
expression (24, 33,34, 47, 48, 54, 60).
Immediate-early or a genes are the first expressed following infection. Those
include ICPO, ICP4, ICP22, ICP27 and ICP47 (62). These proteins are synthesized 24 hours after infection without the requirement of DNA replication; the fll and f32 genes
reach their peak of expression after 5-7 hours infection, f31 genes include these for viral
ribonucleotide reductase and the major DNA binding proteins; examples of f32 genes are
the viral thymidine kinase (TK) and DNA polymerase. The late or y genes include yl
and y2 depending on their time of initial transcription and the requirement for viral DNA
synthesis for their expression (21, 59). The yl genes are expressed somewhat earlier
than the y 2 class, and their expression shows only a partial dependency on DNA
replication. Thus they are first expressed before DNA replication, but they reach their
-maximal level expression after DNA replication (59). The major capsid protein, VP5 is
in the y1 class.
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(5). Translation. Translation of HSV 1 mRNAs occurs in the cytoplasm, on
both free and bound polyribosomes. Structural and most regulatory proteins are
transported into the nucleus.
(6). Assembly and release. After gene expression, nucleocapsid assembly
occurs in the nuclei of host cells. The virus acquires its envelope by budding through
inner nuclear membrane that has been modified by insertion of viral glycoproteins from
the host nuclear membrane (48).

4.

Viral Gene Regulation

Generally, as described above, herpes simplex virus 1 (HSVl) gene expression
occurs as a cascade in an orderly sequence from a (immediate-early, IE), through

fl

(early, or delay-early, DE), and then toy (late, L) gene expression, (2, 7, 8, 17, 20, 22,
23, 26, 40, 61). IE genes expression does not require the DNA replication (11,12,
41,42). Immediate early proteins ICPO and ICP4 perform very important roles in
regulating transcription. Also, IE genes contain numerous other cis-acting sites for
CAA T-box binding proteins shown to affect gene expression. After the virus enters
host cell, they initiate gene expression immediately. ICP27, on the other hand, works
moinly at the post transcription step (3, 6, 9,13, 14, 33,45, 50, 51, 57, 58 ). Both the

fl and y gene expression require the function of IE proteins, ICPO and ICP4 (3,13,14).
Depending on the timing of gene expression and the requirement of DNA replication y
gene expression is divided to two subgroups called yl or "leaky-late" gene that are
transcribed and expressed at low levels prior to viral DNA replication, but after DNA
replication yl genes are expressed at higher levels (25), and the y2 genes are expressed
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after DNA replication (15,22, 23,25,26 ).
My Master's research focuses on the gene regulation of the VP5, major capsid
protein of the virus which serves as a model for the yl gene class. VP5 is a 155 kDa
polypeptide that forms the hexamers of the viral nucleocapsid (4, 7). Exactly how
expression of VP5 is regulated is not well understood. Gene expression studies using
cycloheximide reversal (22, 62) and immediate-early (IE) gene mutants of HSV 1(6,
9,17, 32) showed that IE proteins (ICPO, ICP4, ICP27) are required for yl and VP5
gene expression. Also, workers using DNA synthesis inhibitors have demonstrated that
viral DNA replication is necessary for maximum yl gene expression (5, 21,40).
Many laboratories have shown that VP5 promoter is essentially inactive in
uninfected cells, but is strongly activated by virus superinfection (2, 4, 13, 26). Also,
cotransfection experiments showed that IE genes (ICPO, ICP4, ICP27) are necessary
for transactivation of reporter gene fused to yl promoters (4, 5, 13, 51). However
recent evidence indicates that the major effect of ICP27 in such studies is at the posttranscriptional level (57).
Further work in this laboratory has demonstrated that a specific VP5 promoter
sequence, GGCCA TCTTGAA called leaky-late gene binding site (LBS), is very
important during VP5 gene expression (4).

Using gel mobility shift assay and

footprinting, Chen et al found this LBS is a binding site for cellular protein. Transient
expression assays of bacterial CAT (chloramphenicol acetyl transferase) gene coupled to
the VP5 promoter showed that this LBS is required for maximum transactivation by
superinfection HSV 1.
Current work in this laboratory proved that the protein that binds to the LBS is
YYl or YYl-like protein (36). YYl is a cellular transcription factor (also known as
NF-El, UCRBP and fl), a kind of zinc-finger protein, that has both positive and
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negative regulatory properties depending on the gene context. Also with some genes,
YY 1 performs as initiator role. So YY 1 can function as an activator, a repressor, or an
initiator of transcription (1, 19, 29, 39, 46, 53, 54, 55). Recently, Lee and Shi et al.
found that there is some physical interaction between YYl and SPl proteins (52). And
Seto, Lewis and Shenk have reported that there are interactions between the YY 1 and
SPl proteins during eukaryotic gene expression (53). The new finding in YY 1 research
is that YY 1' s function depends on its orientation on the DNA and its ability to bend
DNA (37).
Based on the previous work, we know that deletion of 35 base pairs (bp)
containing the LBS (YY 1 binding site) of VP5 resulted in a transient expression of a
CAT report gene that was 7-8 fold reduced (4). However, since this deletion includes
more than the YY 1 binding site, adjacent sequences may also be involved.
From these results, a number of important questions arose:
1. Are the promoter sequences adjacent to the YYl binding site involved in VP5
gene regulation?
2. What would be the effect of mutating only the YY 1 site and not the adjacent
regions? Which base pairs are required for YY 1 action and transactivation by HSV 1?
3. How dose YY 1 binding influence VP5 transcription and how does it interact
with viral genes, for example IE (a) regulatory proteins?
These are some of the questions I proposed to address in my thesis research. In
order to solve these problems, I designed my master research as two parts: Project 1 and
Project 2. In project 1, I concentrated on an investigation of YY 1 function in VP5
transcription by subcloning the VP5 promoter, and in the project 2, I designed more
detailed point mutations in the YYl binding site to study YYl's function.

CHAPTER II
THE PURPOSE OF THE RESEARCH IN THIS
THESIS
It has been shown that the leaky-late gene binding site ( LBS, called YY 1

binding site now ) within the promoter of VP5 is very important for regulation of gene
expression (4). This site ( GGCCA TCTTGAA ), located at -64 to -75, was recently
found to be bound by a cellular transcription factor YY 1 ( 36 ). The evidence for
regulation of VP5 promoter activity by YYl is as follows: First, deletion of 35-base
pairs containing the LBS fragment from the VP5 promoter resulted in a7-8 fold
reduction in gene expression from a bacterial CAT (chloramphenicol acetyl transferase)
reporter gene following HSV 1 superinfection. In similar experiments, deletion of half
of the LBS resulted in 3-4 fold reduction of the CAT gene expression. Secondly, gel
mobility shift assays showed that LBS can form two complexes with a host cell nuclear
extract. Gel mobility shift competition assays indicated that the protein forming both
complexes (A and B) with LBS was related to the YY 1 protein, or YY 1 forms the
complex A; probably a proteolytic product of YY 1 forms complex B. Thirdly, protein
binding to the full length VP5 promoter labeled fragment was effectively competed away
with excess amounts of LBS , YY 1 and CFl oligonucleotide, while a nonspecific
oligonucleotide, C2 lacking a YY 1 site had no effect. So the LBS is the specific binding
site for the YY 1 protein. Moreover, partial proteolysis assays of LBF and YY 1
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complexes further identified LBF ( leaky-late gene binding factor) as the transcription

YYl.
Based on the above results, I was trying to answer the following

major

questions in my master research project:
1. What is the function of YY 1 in the capsid protein VP5 gene expression?

In the previous studies, deletion of 35 base pairs (bp ) region containing the
LBS, or YYl binding site (called del. #13) reduced the reporter gene expression 7-8
fold. Since this 35 bp region contains sequences other than the LBS site, I proposed to
create a reporter lacking only the consensces LBS sequence. On the other hand, if the
LBS does play a role in regulation of VP5 transcription, insertion of the LBS back into
the mutated plasmid without LBS should restore promoter activation. Therefore, I
would also create this reporter.
2. In the YY 1 binding site, which base pairs are required for YY 1 function?
3. Assuming YY 1 is the major cellular protein binding the LBS site and forming
the DNA-protein complexes, does it interact with other cellular or viral transcription
factors? If so, how does it interact with them to regulate transcription? To answer these
questions, I designed my master research as two projects:

Project 1:

To create

new mutations within the YYl binding site

of the VPS wild type promoter ( wt VP S) and compare their activities
with wt VPS .
Based on the previous work, using the same VPS(-168) CAT plasmid as wild
type (wt) VP5 and previous constructed promoter mutations, #13 and #6 (Fig.5), I
made two further VP5 constructs. One is a 22 base pair deletion in which LBS (YY 1
binding site ) was deleted, called 13/6. The other one is an insertion of an

16

oligonucleotide including the VP 5 LBS sequence back into the mutated 13/6; this was
called LBS/13/6. I then carried out three major types of experiments to measure the
function of the mutated promoters as compared to the wt VP5:
A. To determine if the newly constructed VP5 promoter mutations were able to
bind YY 1 or not, I carried out gel mobility shift assays using labeled promoter
fragments and HeLa cell nuclear extracts. These experiments would establish DNAprotein complexes were being formed. The mechanism of a gel mobility shift assay is
based on the fact that binding of a protein to a DNA sequence increase the molecular
weight of the DNA probe resulting in a retardation of its mobility through a gel.
B. To measure the function of the mutated promoters, I carried out transient
expression assays in human HeLa cells.

In these assays, promoter activity was

analyzed by its ability to drive expression of linked reporter gene. For this purpose, I
used bacterial chloramphenicol acetyl transferase (CAT) positioned downstream of wt
and mutated VP5 promoters. Transfection of these plasmids into HeLa cells leads to
production of the CAT protein following promoter activation (see chapter III) The final
product acetyl-CAM was dissolved in benzene. After evaporation of the benzene, a
radioactive buffer solution was added, then the Acetyl-CAM was counted by radioactive
counter automatically. This assay allows us to analyze the wt and mutated VPS
promoter activities.
C. To identify the DNA-protein complexes formed by YY 1, I used competition
gel mobility shift assays. First, a Hela nuclear extract (containing endogenous YY 1 )
was allowed to bind to a labeled VP5 promoter fragment. Then an excess amount of
unlabeled DNA fragment is added into the reaction tube. If the unlabeled DNA fragment
contains a suspected protein binding site, it will bind the nuclear extract protein quickly,
and we will see a reduced binding of the protein to the labeled DNA probe. In these
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experiments, the ability of specific unlabeled oligonucleotides were tested for their
ability to inhibit complex formation.

Project 2.

To make point mutations on LBS of wt VP5 and

compare their function to wt VP5.
Even if I can get more information about LBS function in VP5 gene expression
from project 1, I still think that it is just very general information. For a more detailed
analysis, I should make point mutations within the LBS sequence to see which base
pairs are performing the key role in regulation of VP5 gene expression. So, I designed
two point mutations in LBS. I have mutated the wild-type LBS (GGCCATCTTGAA)
to either ATCTATCTTGAA or GGCCA OAT CTAA ( mutations underlined). Both the
mutations have a new Bgl II site (wt VP5 dose not have BglII cut point.) making
further work very convenient.
To construct these mutations, I used PCR (polymerase chain reaction ) with
mutant oligonucleotide primers. On my wt VP5 promoter, one end has the Sal I cut
point, the other end has Hind III site. For each point mutation, I designed the Sal I
(sense)!Bgl II ( anti-sense) and Bgl II(sense)/Hind III ( anti-sense) primers. Then I

used the PCR technique to am pl ify the mutated region and ligated this into wt VP5 big
fragment cut by Sal I and Hind III ( the detailed information is in the chapter III).
Mutation 1 and mutation 2 have only a few base pairs different from the wt VP5
promoter. All the rest parts of the plasmids are exactly same as wt VP 5 plasmid. In the
project 2, I would use gel mobility shift assay, CAT assay and competition gel mobility
shift assays to test the functions of the point mutations in VP5 promoter.

CHAPTER III
MATERIALS and METHODS
1. Materials

Plasmids

Plasmid pVP5 (-168) CAT contains the wild-type (wt) herpes simplex virus 1
(HSVl) capsid protein (VP5) promoter sequence from -168 to -4 base pairs (bp) from
the cap site linked to the bacterial chloramphenicol acetyl transferase (CAT) gene.
pVPS(-168) CAT was provided by E. Blair and E. Wagner, University of California,
Irvine, CA. Plasmids VP5 #6 and #13 were created from p VP5 (-168) CAT in this
laboratory as described previously (4) (Fig.5). VP5 #6 contains a 12 base pairs Bgl II
linker inserted between -80 and -81 bp. of pVP5 (-168) CAT. VP5 #13 (also called
deletion #13) (4) contains a deletion of 35 base pairs from -59 to -93 including the
leaky-late gene binding site (LBS). Further specific deletions or mutations in the wildtype VP5 (wt VP5) promoters were produced from above plasmids as described below.
All plasmid DNAs were prepared in one of the two ways: ( 1) By the alkaline lysis
method (31) as modified by this laboratory (4) and further purified by CsCl buoyant
density centrifugation to isolate supercoiled DNA for transfections. (2) By the use of
Qiagen 500 tips (purchased from Qiagen company) to isolate supercoiled forms
following described by the manufacture.

Oligonucleotides
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TABLE 1 Oligonucleotides

Name

Source of Sequence

LBS

LBF binding site
ofHSV-1 VP5

CFl

CFl binding fite of
5' GGGCGCGAGAAGAGAAAATGGTCGGGC
murine c-myc promoter

Sequence
5' CCAGGATCCAGGGCCATCTTGAATGGATCCTGG

YYl

YYl binding site of P5 5' GATCTCCATGGTTTTGCGACATTTTGCGACA
of adeno-associated virus

C2

µE3 binding site of murine

5' CCTTGCCATGACCTGCTTCCT

TABLE 2 PCR primers

Name

Location

Sequence

San

Mut.1and2

CTGGGTTGAAGGCTCTCAAGGGC

HandIIl

Mut.l and 2

CTTAGCTCCTGAAAATCTC

Mut.1 a

Mut. 1

GCATTCAAGATAGATCTGGTCCAAAAGC

Mut.1 b

Mut. 1

CTTTTGGACCAGATCTATCTTGAATGCACC

Mut.2 a

Mut. 2

CGGGTGCATTAGATCTGGCCCTGGTC

Mut.2 b

Mut. 2

ACCAGGGCCAGATCTAATGCACCCGTC
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A. The following double-stranded oligonucleotides were used as unlabeled
competitors in gel mobility shift assays (Table 1): (1) LBS, contains the binding site for
the leaky-late gene binding factor (LBS or YY 1 binding site) from the VP5 promoter
with BamHl sites at each end was synthesized by the vollum institute, Oregon Health
Science University (OHSU). It is composed of 33 base pair with the following
sequences: CCAGGATCCA GGGCCATCTT GAATGGATCC TOG; (2) CFl,
contains the binding site for the murine transcription factor called common factor 1
(CFl) from the murine c-myc gene, a gift from K. Riggs and Calame Columbia
university. It has 27 base pair with the following sequence GGGCGCGAGA
AGAGAAAATG GTCGGGC; (3) YYl 7/8 consists of a 31 bp fragment as:
GATCTCCATG GTTTTGCGAC ATTTTGCGAC A. It was provided by E. Seto and
T. shenk; (4) SPl (purchased from Promega. The sequence was not showed); (5) C2
containing the binding site for the murine IgH intronic enhancer the sequence is:
CCTTGCCATG ACCTGCTTCT.
B. Oligonucleotide used as single-stranded primers in the polymerase chain
reaction (PCR) mutagenesis are shown in Table 2. They were synthesised by the
oligonucleotide facility, department of biochemistry (OHSU). (1) Distal primers: Sal I
and Hind III as the distal primers, their sequences are: CTGGGTTGAA
GGCTCTCAAG GGC and CTI AGCTCCT GAAAATCTC the Hind III primer primes
for the antisense strand of the mutated fragment. (2) Mutation 1 sequences: To mutate
the LBS, two new sequences including Bgl II restriction site were designed, mutation 1
a is: GCATT CAA GA TA GATCTGGT CCAAAA GC and primes the direction to the Sal
I primer, and mutation 1 bis: CTTTTGGACC AGA TCT ATCT TGAATGCACC to the

Hind III direction. (3) Mutation 2 sequences: Mutation 2 a is: CGGGTGCA TT
AGATCTGGCC CTGGTC priming the direction to the Sal I primer and mutation 2 bis:
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ACCAGGGCCA GATCT AATGC ACCCGTC priming to the Hind III primer.
All the primers used in point mutations were synthesised by OHSU described
before.

Cells and virus
HeLa cells (A TCC, CCL2,purchased form GIB CO) (4) were grown at 37°C
with 5% C02 atmosphere in Dulbecco's modified Eagle medium (DMEM) containing
10% heat-inactivated calf serum (Hyclone Labs, Inc), penicillin ( lOOU/ml), and
streptomycin ( 100 ug/ml). The vhs-lmutant of HSV 1 (KOS), defective in a virionassociated host shut off function which located in the UL41 gene (5, 43), was provided
by G.S. Read, Loyola University of Chicago.

Nuclear Extracts
Nuclear extracts (NE) prepared by the following method of Dignam (4, 36) from
either uninfected (mock-infected) HeLa cells or cells infected for 8 hrs. by HSV l(KOS)
at a multiplicity of infection of 10-15 protein concentration of extracts were determined
by the lowery method(36, 43). NE was diluted to lug/ul for use in gel mobility shift
assays.

Radioactive products
32P-ATP and 32P-CTP were purchased from NEN. company, 3H-Acetyl from
OHSU.

Enzymes
Restriction endonucleases were from Bethesda Research Labs., Inc. (BRL) and
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New England Biolabs (NEB) packaged with the reaction buffer. (KGB was also used a
rotine reaction buffer) (31). Bacterial chloramphenicol acetyl-transferase (CAT), Sacetyl coenzyme A synthetase, and coenzyme A were purchased from Sigma Chem. Co.
Kienow fragment of DNA polymerase, T 4 DNA ligase, RNase were from BRL. Taq
polymerase and MgCI 2 buffer were purchased from OHSU. Calf intestinal phosphatase
(CIP) was purchased from Sigma company.

Sequenase enzyme, buffers, and

dideoxynucleotides for sequencing were purchased as the Sequenase 2 kit from U.S.
Biochemical Company.

2. Methods

Construction of Subcloned VPS Promoter Mutations.

A. Deletion 13/6. Plasmids #13 ( without LBS, including Bgl II linker) and #6
described before, lOOug for each one, were cut by enzymes Nco I and Bgl II (3-4U/ul),
and incubated at the 37°C for 2 hrs. Then added 1/10 volume of the lOX stop dye,
loaded and ran samples on 1% agaros gel 600-800 volts hr. 4 binds were obtained (
both Ncol and Hand III have one cut site), 2 big ones (about 3.1 Kb.) and 2 small ones
(about 0.6 Kb.). DEAE paper was used to isolate the DNA fragments from the agorase
gel, and higher concentrated salt solution was used for eluting by lM NaCL Finally,
the DNA was dissolved in TE ( lOmM Tris-Cl, lmM EDT A). The large piece of #13
and the small piece of #6 were ligated by using T4 ligase, with incubation at 16°C
overnight. The ligated plasmid called 13/6 was transformed into bacteria E. coli
HB 101. The plasmid DNA was prepared as described earlier.
B. LBS/13/6. Oligonucleotide LBS is a 33 base pair double-stranded DNA (Table
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Fig. S. Mapping of deletion and insertion constructs in the VP5 promoter.
The insertion of #6 is just the original VP5 plasmid plus the Bgl II linker, the
#13 deletion of 35 base pairs plus Bgl II linker. ( Chen. 1992.)
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Fig.6

GGC2~TCTTG~A
C2GBTAGA.i:~CT~

Construction of subcloned mutations
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TG CCGT
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(Tablel) which includes GGCCATCTTGAA (the YYl binding site). There are two
BamHI sites at the both ends of the YY 1 binding site. Then 13/6 was restricted by
Bglll and the LBS oligonucleotide by BamHI as by the usual protocol described before

and ligated together to get the plasmid LBS/13/6 (Fig. 6).

Construction of point mutations in wild type VP5 promoter
In the project 2, two site-directed mutations were designed. The techniques used
were the same for each one.
PCR primers for the Sall and Hindlll sites of the wt VP5 promoter were
designed (Table 2). Hind III primes for the antisense strand, while Sall primes for the
sense strand. Two Bgl II primers in each point mutation were designed, one was
directed to the San site and the other one was directed to the Hind III. Each Bgl II
primer contains the mutated sequence (Table 2). BgnI mutation 1 a and mutation 2a
were directed to the Sal I site, mutation 1 band mutation 2 b were directed to the Hind
III. PCR reactions were as follows: The original wt VPS plasmid served as a template
using the DNA primer combinations listed below. Each reaction contained 25mM
magnesium, 2mM dNTPs and Taq polymerase 0.5U in a reaction volume of 100 ul.
Primer Sall was added with primer Bglll la or 2a, while primer HindIII was added
with primer Bglll lb or 2b. Three temperature programs for the thermal cycler
(Perkins-Cetus) were used for obtaining PCR fragments: ( 1) denaturing cycle: 95°C for
three minutes followed by 45°C for 30 seconds, (2) amplification step: 21 cycles, each
comprised of 45 seconds at 94°C, 30 seconds at 42°C, then 72°C for two minutes, (3)
elongation step: 72°C for four minutes.
The PCR fragments were trimmed by Sall and Bglll or BgnI and Hindlll
digestion. Plasmid VP5 #6 was digested with Hindlll and Sall, the large fragment was

/"'
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isolated as described before. This piece plus either mutation 1aand1 b fragments from
PCR or mutation 2 a and 2 b fragments from PCR were ligated together as described
under subcloning methods.

DNA sequencing
DNA sequencing was carried out using the dideoxynucleotide chain termination
method (Termination reaction method) with the Sequenase 2 kit from US Biochemical
Co (USB). The following protocol from USB was used:
Plasmid DNA (3ug) was added to 20ul 0.1 NaOH/0.2mM EDT A and incubated
at room temperature for five minutes. The DNA was neutralized by adding 2 ul of lOM
ammonium acetate, precipitated by adding 60 ul ethanol, chilling on ice for 15 minutes,
and spun for 20 minutes at 1500 rpm at 4°C. To precipitate the DNA pellet was rinsed
with 70% ethanol and then dissolved in 7ul water. To anneal the Sall primer (from
USB) to the denatured DNA template the plasmids and the primer were heated at 65°C
for two minutes in sequencing reaction buffer, and then allowed to cool to below 3.SOC.
For labeling, the following kit reagents were added to the cooled annealing mixture:
DTT (lul), dGTP labeling mixture (2ul), and 8-fold diluted Sequenase enzyme (2ul).
One half microliter 32P dA TP or dCTP (NEN) was added as the radionucleotide label.
This mixture was incubated at room temperature for 2.5 minutes.
For each sample to be sequenced four termination mixture tubes were prepared
containing 2.5ul of dideoxynucleotide termination mixtures (of ddGTP, ddA TP,
ddTTP, or ddCTP) and warmed to 37°C. Aliquots of the labeling reaction (3.Sul) were
added to each termination mixture for that sample and incubated at 37°C for five
minutes. To stop the reaction, 4 ul of stop solution were added to each reaction tube.
To determine the sample DNA sequence, 3.5ul from each of the samples

_I'
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reaction tubes were loaded onto a 6% polyacrylamide sequencing gel (prepared using
USB protocal). Gels were electrophoresed at 1,700 volts, 35-45 watts, for 2 hrs.
3MM paper was used to support the gels during vaccuum drying. The gel was exposed
to Fuji RX film for 8 hours with an intensifying screen at

-7~C

and then developed by

atandard procedures.

Gel shift mobility assays
Sall! HindIII fragments were used in the gel mobility shift assays from: wt VP5

and VP5 promoter mutants, 13/6, LBS/ 13/6, and point mutations 1 and 2. The
fragments were isolated on DEAE paper as described previously. The ends of each
promoter fragment were filled-in using the Kienow fragment with

32 P

dCTP was

incorporated as the radionucleotide label. For each assay, 0.6ng of the DNA probe, lug
of poly (dl-dC) and lug of HeLa nuclear extract were mixed in a reaction buffer
providing a final concentration of 6mM Tris-HCI (pH 7.9), 40mM KCl, 2mM EDT A,
0.2 mM dithiothreitol, and 8% (vol./vol.) glycerol in a total volume of 20 ul. After
incubating at room temperature for 30 minutes, 2 ul of 0.25% bromophenol blue dye
were added. The samples were electrophoresed at 4°C, 250 volts, through a 4%
polyacrylamide gel in non-recirculating buffer (NRB, also known as DBB2) (31, 36).
The gel was vacuum dried on 3MM paper and exposed to Fuji RX film at -70°C. The
film was developed as previously described ( 10, 16).
For the competition assays, the only difference from the basic gel mobility shift
assay described above was adding 100-150 times molar excess of various unlabeled
oligonucleotides (Table 1) before adding the nuclear extract to the reaction.

Transient gene expression CAT assays
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The calcium phosphate precipitation method was used for transfection (4, 18,
36). HeLa cells were grown at 37°C under 5% C02 atmosphere in Dulbecco's modified
Eagle medium. (DMEM, from GIBCO Laboratories) containing 10% heat inactivated
calf serum (HyClone Labs, Inc.), streptomycin lOOug/ml, and penicillin 100 units/ml.
When the cells were 80-90% confluent, they were seeded into 35mm well cluster dishes
at 3 x 105 cells per well in DMEM containing 10% fetal bovine serum. The medium
was changed after 17 hours. After seeded 20 hours, the cells were transfected with
various reporter plasmids. The tested plasmids 8ug and pUC18 (without CAT gene
)8ug were added to 0.25 ml of 2X HBS buffer (4, 31, 38). Then, 0.25mM CaCl 2
(0.25ml) was added with gentle bubbling. This was incubated at room temperature for
30 minutes. The DNA mixture was applied to the HeLa cells, which were then
incubated at 37°C for four hours. The cells were glycerol shocked 4-5 hr. after
transfection for one minute (15% glycerol in DMEM-10% inactived fetal serumpenicillin (100 units/ml)/streptomycin (lOOug/ml). The cells were washed three times
with PBS-A (0.14M NaCl, 2.7mM KCl, 4.3mM

N~HP0 4 ,

l.5mM KH 2 PO). Then

DMEM containing 10% fetal serum was added to the cells again and the cells were
incubated at 37°C in a humidified incubator for 22 hours. The cells were superinfected
by HSVl (vhs-1) in PBS/ 10% glucose 1% inactivated calf serium at a multiplicity of
infection at 3 and incubated at 37°C for one hour. Then the virus was removed from
the cells, DMEM with 10% fetal calf serum was added and they were incubated at 37°C
before. The cells were harvested 48 hours after transfection (4) (see the chart attached
next page).
The cells were washed, lyzed, and assayed following the method of Nordeen, et
al. (38). Briefly the CAT assay experiment can be described as the followings: The first
step was to get radioactively labeled acetyl-CoA from the labeled 3H-Na-acetate (NEN
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Research Products, Inc., 3.3 Ci/mmol, 10 mCi/ml) into cetyl-chloramphenicol using the
coupled reaction with Acetyl-CoA synthetase. Then one can get the radioactiely labeled
Acetyl-Chloranphenical ( Acetyl-CAM) under the function of CAT. And the AcetylCAM can be extracted by benzen. The solvent was then evaporated. Finally AcetylCAM was quantitated by scintillation counting (4).
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CHAPTER IV
RESULTS

According to this laboratory's recent findings ( 4 ), the herpes simplex virus
leaky-late gene binding site, (LBS, now called the YYl binding site ), located between
-64 and-75 in the VP5 promoter, is required for maximum transactivation of the VP5
gene (details described in chapter I ). Furthermore, this laboratory identified a new
cellular protein factor, the LBF (leaky-late gene binding factor) that binds to this site.
(4). And further work in this laboratory (36) has proven that the LBF is identical to the
previously described cellular factor called Yin-Yang 1 (YY 1, also known as UCRBP,
CFl, F-ACTl, NF-El ). YYl has been known performing different functions in
different gene expression (56).
From these previous studies, many new questions arose. For the purpose of
this thesis, the main questions to be answered are the following:
1. What is the function of the LBF ( YY 1 ) and its binding site in the major

capsid protein, VP5, gene expression?
2. How does the YY 1 binding site ( LBS ) function in regulating VP5 gene
expression?
3. Assuming YY 1 is the major cellular factor to bind LBS, what are the
interactions between YY 1, viral regulatory proteins and cellular transcriptional proteins
?
In order to answer these questions and understand the mechanisms of the LBS
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(leaky-late gene binding site, or YY 1 binding site ) in the gene regulation of herpes
simplex virus 1 (HSVl), two projects were designed in my Master thesis research.
Project 1 focused on the subcloning of mutations in the VP5 promoter and
analysis of their functions. In this project I investigated the function of mutated VP5
promoters which either lacked LBS or had the LBS sequence reinserted.
In previous work, S. Chen constructed large deletions in the VPS promoter that
included the YYl binding site (LBS) (4) (Fig. 5). To construct a smaller, more defined,
mutation in the YY 1 binding site of the VP5 promoter, I constructed the following
mutations: Deletion 13/6: Deletion #13 that contains the Bgl II site without LBS and
insertion #6 that contains the Bgl II site were cut by Sal I/Hind III, then the small
fragment of deletion #13 was ligated to the big fragment of insertion of #6. The new
plasmid, called 13/6, has a 22 base pairs deletion that includes the YY 1 binding site
(LBS ) and the insertion of a 12 base pairs Bgl II linker(Fig. 6). Reinsertion mutation,
LBS/13/6:

Another important subcloned mutation in project 1 is the reinsertion of

oligonucleotide LBS. Deletion 13/6 was cut by Bgl II, and oligonucleotide LBS was
cut each end with Bam HI. and then both the above parts were ligated together. Because
of the matching part of Bgl II and Barn HI site, GATC, the reinsertion of LBS mutation,
called LBS/13/6, can not be cut by either Bgl II or Barn HI. So the reinsertion of the
LBS mutation could be easily tested by lack of Bgl II and Bam HI cutting ( Fig 6)
Project 2 focused on a point mutational analysis of the YY 1 binding site. The
purpose of the project 2 was to search for which base pairs have key roles in VPS gene
regulation. In order to observe the function of different regions of the YY 1 binding site,
two point mutations, mutation were designed. Mutation 1 changed original YY 1
binding site, GGCCATCTTGAA, to ATCTATCTIGAA, while mutation 2 changed the
site to GGCCAGATCTAA. Both the mutation 1 and mutation 2 contain a Bgl II site,
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AGATCT, that facilitates later experiments easier. Both mutations were created by
using in vitro synthesized oligonucleotides bearing the mutated sequences, PCR, to
amplify the mutated regions, and subcloning back into the original plasmid(s).
The main experimental and techniques involved in these projects include
plasmid construction, DNA preparation, DNA sequencing, gel mobility shift assay and
transient gene expression assay (see the chapter III). In this chapter, I will describe the
results of Project 1 and Project 2.

1. Project 1

As described above, the purpose of Project 1 was to determine the function of the
subcloned mutations, deletion 13/6, and the YY 1 binding site reinsertion LBS/ 13/6, as
compared to the wild-type (wt) VP5 promoter.

A. Gel mobility shift assays with wild-type and mutant VPS promoter
fragments.
To verify the removal of LBS in deletion 13/6 and reinsertion in LBS/13/6, gel
mobility shift assays were carried out by using 32P-labeled VP5 promoter fragments
from the wild type (w.t.) and mutant constructs. Nuclear extracts from infected HeLa
cells were used (we have previously shown that uninfected and infected nuclear extracts
give the same LBS complexes). Results of the first gel mobility shift is shown in
Figure 7. As described previously (4), two major complexes were formed, complex A
(of lower mobility) and complex B (of higher mobility), with the wt VP5 promoter and
the mutant LBS/13/6 promoter fragments(Fig.7. lanes 2 and 6). However when
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Fig.7 Gel mobility shift assay I. The data were described at the
Table 3. Lanes 1, 3 and 5 were 32P labeled promoter fragments from
wt VP5, 13/6 and LBS/13/6. Lanes 2, 4 and 6 were same fragments
incubated with the nuclear extract of the infected HeLa cells. Two
complexes were formed, A and B. in lanes 2 and 6. Electrophoretic
mobility shift polyacrylamide gel (4%) was run at 250 volts for 2
hours in nonrecirculating buffer.
"A" is the complex A. "B'' is the complex B and "P" is the probe.
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TABLE 3.

Gel mobility shift assay I
1

2

3

4

5

6

wt VPS probe

+

+

-

-

-

-

13/6 probe

-

-

+

+

-

-

LBS/13/6 probe

-

-

-

-

+

+

NE+polydldC

-

+

-

+

+

YYl complex A Formed

-

+

-

-

YYl complex B Formed

-

+

-

-

-

NE is the nuclear extract of the infected HeLa cells. PolydldC is
an unspecific DNA sequence to neutralize the unbinding NE proteins.
There are six reactions, the first lanes 1, 3 and 5 are 32P-labeled promoter
fragments from wt VP5 (-4 to -168), 13/6 and LBS/13/6 probes only and
the other three are incubated NE (lµg) with probes and polydldC. Two
complexes, called complex A and B, located at the middle and lower parts
(lanes 2 and 6) and free probes (lanes 1, 3, 4, and 5) appeared.
Electrophoretic mobility shift polyacrylamide gel (4%) was run at 250
volts for 2 hours in lx nonrecirculating buffer (see fig. 7).

+
+
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deletion 13/6 (without YYl binding site) was used, essentially no YYl complexes were
formed (Fig.7. lane 4). The results of this experiment are summarized in Table 3.
These results confirm that mutation 13/6 lost the YY 1 binding site, and LBS/13/6 had
regained it.

B. Complexes A and B are formed by cellular factor YYl.
To confirm that the complexes (A and B) were indeed formed by YY 1 (LBF),
the following competition gel mobility shift assays were performed. Oligonucleotide
LBS, containing the YY 1 binding site, or oligonucleotide C2 lacking the LBS sequence
were added at 150-fold molecular excess to the labeled probe 10 min before the nuclear
extract was added. After 20 minutes of incubation at room temperature, the samples
were analyzed by electrophoresis in 4% polyacrylamide gels ( methods described in
Chapter Ill). The results showed that both the complex A and B seen with the wt VPS
and reinsertion LBS/13/6 promoter fragments were inhibited by the LBS oligonucleotide
, but not by the oligonucleotide C2 (Fig.8 ). These results are summarized in table 4.
We can conclude from this experiment that both wt VPS and reinsertion mutant,
LBS/13/6, have a specific binding site for the cellular factor YYl, and this site is absent
from mutation 13/6.

C. The binding of YYl (LBF) is required for optimal transactivation of
the wild-type VPS promoter by superinfected HSVl.
To compare the function of the mutant VPS promoters with the wild type and to
analyze the gene regulation function of complex A and complex B, the wt VPS, deletion
of 13/6, reinsertion of LBS/13/6 promoters were tested in transient expression assays
for bacterial CAT (chloramphenical acetyl-transferase) gene expression. HeLa cells
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Fig.8 Competition binding assay I. The description was at the
Table 4. Lanes 1. 5 and 9 without NE, all other lanes with NE
200-fold molar excess of LBS oligonucleotide was added to Lanes
3, 7 and 11. Oligonucleotide C2 was added to the lanes 4, 8 and 12.

TABLE 4

Competition binding assay I

1

2

3

4

5

6

7

8

9

10

11

12

wt VPS probe

+

+

+

+

-

-

-

-

-

-

-

13/6 probe

-

-

-

-

+

+

+

+

-

-

-

-

LBS/13/6 probe

-

-

-

-

-

-

-

-

+

+

+

+

NE +polydldC

-

+

+

+

-

+

+

+

+

+

+

Oligo LBS

-

-

+

-

-

+

-

-

+

-

Oligo C2

-

-

+

-

-

-

-

+

-

+

+

-

-

+

YY 1 complex A Formed

-

-

-

+

-

+

YY 1 complex B Formed

-

+

-

+

-

-

-

-

-

+

-

+

Based on the tabel 3 data, this experiment is the further work to see if the complexes can be competitived
by specific oligonucleotide LBS and C2. Oligonucleotide LBS is a specrific YYl binding site. C2 is an
another specific oligonucleotide without YY 1 binding site. When LBS was added at 200 folds molar excess
of probe, it forms the complexes with YY 1 contained in NE without showing on the film, so complexes A and
B were gone (lanes 3 and 11). But C2 can not bind YY 1, so YY 1 still binded to the LBS in the probes wt VP5
and LBS/13/6 (lanes 4 and 12).
w
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were transfected with 8 µg of the three VP5 target plasmids, and twenty hours later
they were superinfected with HSVl (vhs-1). The cells were harvested 26 hours after
superinfection and lysates were prepared and used for CAT enzyme assays. A pUC18
plasmid (lacking the CAT gene) was used as control in this experiment. The results are
shown in Figure 9. If the wt VP5 CAT expression following superinfection is
considered to be 100%, the deletion 13/6 reduced the CAT yield to 47.5% of the wild
type level, and the reinsertion LBS/13/6 was reduced to 22.8%. The CAT activity with
pUC18 and all of the VP5 CAT plasmids without superinfection by HSVl are
approximately the same (about 1.0% relative to wt induced levels). This value is also
about the same as that obtained with cells without transfected plasmids, i.e. background
level.(Fig.9 and Table 5).
From these transient expression assay results, I conclude the following: (1)
Deletion of YY 1 binding site (LBS) produced a two-fold reduction in induced CAT
activity. (2) Surprisingly, reinsertion of YY 1 binding site ( the LBS oligonucleotide)
did not restore the CAT activity, but further reduced it to 114 that of w.t. VP5.
Additionally, based on the above results, it can be seen that during the transactivation
event, not only YY 1 but also viral factors perform important roles since all the CAT
assays without HSV 1 superinfection are almost at background level. Previous results
from this laboratory and others indicated that the viral factors involved are the immediate
early proteins, ICP4, 0 and 27.

2. Project 2

Project 2 involved designing and testing point mutations in the VP5 promoter.
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60.0%
46.0%
40.0%
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20.0%
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72%

0.0%

7.6%
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PUC10 I

PUC10 U

wt I

'Niu

13!6 I

13.16 U

LBSl1 3/6 I L8St1 3/6 U

Fig. 9 Induction of transient VP5 promoter - CAT constructs I.

In

project 1, there are three plasmids compared each other: wt VP5, 13/6 in
which LBS sequence was deleted and LBS/ 13/6 in which LBS was
reinserted back to 13/6. This Fig. shows that if we consider wt VP5 CAT
yield as 100%, while the 13/6 is 46.0% (S.D. is 15.2%) and LBS/13/6
is 22.9% (S.D. is 12.0%). The "I" means superinfection by HSVI and
the "U"

means unsuperinfection.

In this experiment, all the

unsuperinfection cells' CAT assay were near the background.

TABLE 5.
W.t

puc18
CAT

1·

% of

ub

% of

1·

ub

13/6
% Of wtC

la

wtc

wtc

Assay

Transient gene expression I

% of

LBS/13/6

ub

% of wtC

la

wtc

% of

ub

% of

wtc

wtc

1

430

5.8%

470

6.4%

7353

453

6.2%

4871

66.2%

508

6.9%

2909

39.6%

491

6.7%

2

688

0.4%

1554

1.0%

155461

543

0.3%

73192

47.1 %

510

0.3%

17842

11.5%

465

0.3%

3

205

10.7%

210

10.9%

1921

194

10.1 %

784

40.8%

218

11.3%

352

18.3%

218

11.3%

4

497

14.0%

437

12.3%

3553

437

12.3%

1062

29.9%

435

12.2%

787

22.2%

404

11.4%

a.
b.
c.

Superinfection briefly written. It is the CAT yield coming from the cells that were superinfected by HSVl.
Unsuperinfection briefly written. That is the CAT yield coming from the cells that were not superinfected by HSVl.
The percentage compared with superinfected wt VPS CAT values.

This table is to show the radioactivity reading by the automatic equipment, the unit is cpm. The
result is from 24 µl lysate that total amount is 100 µ1, coming from 75cm2 dish cells. Four times CAT
assays have been done. According to this table, we get the average percentage of 13/6 CAT yield
46.0% (S.D. is 15.2%) and LBS/13/6 CAT yield 22.9% (S.D. is 12.0%) compared with wt VP5 that
is considered as 100% CAT yield (see Fig.9).
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The goal of project 2 was to find out which base pairs are most important for viral
transactivation. Two point mutations were designed (Chapter III), called mutation 1
(mut.1) and mutation 2 (mut. 2). Mut. 1 has 3 base pairs changed at the 5' end of the
LBS (YY binding site) and mut. 2 has 4 base pairs changed at the 3' end of the YY 1 site
(Fig.11). These point mutations were verified by DNA sequencing( Fig. 12). All the
techniques and experiments involved in project 2 were approximately same as project 1.
The results are following:

A. Mutations 1 and 2 both lost YYl binding sites.
Mutation 1 and 2 were tested in gel mobility shift assays for loss of YY 1 binding
(Fig. 13). These assays showed that both mut. l and mut.2 resulted in lost of the
complex A completely (Fig.13, lanes 5 and 6 ), and severe reduction in complex B (Fig.
13, lane 5 and 6 ). The data from this experiment are summarized in Table 6. These
results indicate that both the distal GGCC and proximal TCCG are important for YY 1
function.
The Fig. 14 showed the competition gel mobility shift assay in mutation 2.

B. Different regions in LBS perform different function during VP 5
promoter transactivation for binding factor YYl.
To test the function of mut.1 and mut. 2, similar transient expression CAT
assays were carried out as in project 1 . The results showed that both mut.1 and mut.2
reduced the CAT activity induced by HSVl super infection. However, the level of
reduction for each mutation was not same. Mut.1 reduced the CAT activity to 12.5%
and mut.2 reduced it only to 73.7% of wt levels(Fig. 15). The data summarizing this
experiment are presented in Table 7. These results strongly suggest that different
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Use of the PCR technique for the mutation 1 and 2.

This chart just shows one mutation forming procedure,
but the principle is same. Bgl II is the designed primer to create
a new fragment including Bgl II site that have two advantage:
(1), It has mutated sequence. And (2), It will be very useful for
the screening after transformation, because the VPS W.T. does not
have Bgl II site.
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Sequence of Point Mutations
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Fig.12 DNA sequence of point mutations. USB Kit was used
in the DNA sequencing reaction. Compared with the wt VPS,
mutation 1has3 base pairs difference and mutation 2 has 4 base
pairs difference. 111e arrow region is the mutant part. 111e
detailed description is in the chapter III.
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regions in LBS have different functions. Even though both regions are very important
in forming the YYl-LBS complexs, the roles in gene expression of wt VP5 are not
same.

C. YYl may interact with SPl protein during wild type VPS gene
expression.
It was noticed in gel mobility shift assays that there was a DNA-protein complex
band of lower mobility above the complex A (Fig.14). Based on the construction of wt
VPS promoter used in these projects, a potential SPl ( SPl binding site located at the
downsdream of YYl binding site at around -40 bp relative to the mRNA start site) was
speculated this complex band of lower mobility might be formed by SPl binding.
Therefore, I used an oligonucleotide containing an SPl binding site as a competitor in
the gel mobility shift assays . This resulted in the dissappearance of all the lower
mobility band present in the gel mobility shift assays of wt. VPS, mut.1 and mut.2
promoters were gone (Fig.16, complex C). This results indicated that this lower
mobility band was formed by Spl-DNA binding. These results suggested that YYl
may interact with SPl during wt VPS transfection.
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Fig.13 Gel mobility shift assay II. The data were described at
the Table 6. Lanes 1,2 and 3 were 32P labeled promoter fragments
from wt VP5, mut.1 and mut. 2. Lanes 4, 5 and 6 were same
fragments incubated with the nuclear extract of the infected Hel..a
cells. Two complexes were formed, A and B, in lanes 4 and a very
ligh band formed in lane 6. Electrophoretic mobility shift
polyacrylamide gel (4%) was run at 250 volts for 2 hours in
nonrecirculating buffer.
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TABLE 6.

Gel mobility shift assay II

1

2

3

4

5

6

wt VP5 probe

+

-

-

+

-

-

Mut 1

-

+

-

-

+

-

Mut 2

-

-

+

-

-

+

NE+polydldC

-

-

-

+

+

+

YYl complex A Formed

-

-

-

+

-

-

YYl complex B Formed

-

-

-

+

*

*

The condition of this experiment was same as project 1 (table 3),
the only difference was using Mut. 1 and Mut.2 fragments instead of the
13/6 and LBS/13/6 fragments. The first three areprobes only and the rest
three areincubated NE with probes and polydidC.
The marker "*" indicates that there was a smear band located at
the complex B location. This band looks like very light, the amount of
Mut. is a little more than Mut. 2.
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Fig.14 Competition binding assay II. The description was at the Table 7.
Lanes 1, 5 and 11 without NE, all other lanes with NE. 1.50-fold molar
excess of LBS and C2 oligonucleotides were added to Lanes 7, 13 and 8 14.
100-fold as probe of oligonucleotides CFl and YYl were added to lanes
3, 9, 15 and 4,10, 16.

"C" is another complex.

TABLE 7.

Competition binding assay II

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

wt VPS probe

+

+

+

+

-

-

-

-

-

-

-

-

-

-

-

-

Mut 1 probe

-

-

-

-

+

+

+

+

+

+

-

-

-

-

-

-

Mut 2 probe

-

-

-

-

-

-

-

-

-

+

+

+

+

+

+

NE+polydldC

-

+

+

+

-

+

+

+

+

+

-

+

+

+

+

+

Oligo LBS

-

-

-

-

-

-

+

-

-

-

-

+

-

Oligo C2

-

-

-

-

-

-

+

-

-

-

-

+

-

-

Oligo CFl

-

-

+

-

-

-

-

-

-

+

-

-

-

-

-

+

-

Oligo YYl

-

-

-

+

-

-

-

-

-

+

-

-

-

-

-

+

Complex A

-

+

20%

30%

-

-

-

-

-

-

-

-

-

-

-

-

Complex B

-

+

*

*

*

*

*

*

*

*

*

*

*

*

*

*

This work was the further experiment based on the gel mobility shift assay II. The marker "*" is
same meaning as table 6. Both oligonucleotide CFl and oligonucleotide YYl have the DNA-protein
binding sites. In this experiment, they are competiting with LBS contained in the probe, just like the
function of oligonucleotide LBS. The amounts of oligonucleotide LBS and C2 were 150 folds as probe,
oligonucleotide CFl and YYl are 100 folds as the probes. Lanes 3, 4 showed CFl and YYl binded
most proteins; but not completely, still 20% and 30% left those binded the probe DNAs.
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40.0%
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..

PUC18 I

PUC18 U

wt I

wt U

Mut.1 .I

ML.t.1 .U
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Fig. 15 Induction of transient VP5 promoter - CAT constructs II. In
project 2, there are three plasmids compared each other: wt VP5, Mut.
1 in which LBS sequence was changed 3 bp different at the 5" part and
Mut. 2 that is 4 bp different at the 3' part. This Fig. shows that if we
consider wt VP5 CAT yield as 100%, while the Mut.1 is 12.4% ( S.D.
is 1.4%) and Mut. 2 is 74.0% (S.D. is 3.8%).

The "I" means

superinfection by HSVl and the "U" means unsuperinfection. In this
experiment, allthe unsuperinfection cells' CAT assay results were near the
background.

TABLE 8.
puc18
CAT

18

% of

ub

wtc

Assay

Transient gene expression II

wt VPS

% of

1a

ub

wtc

Mut.l
% of

18

wtc

% of

Mut.2
ub

wtc

% of

Ia

wtc

% of

Ub

wtc

% of
wf

1

803

1.3%

1173

1.9%

62240

1234

2.0%

7122

11.4%

1152

1.9%

47723

76.7%

1022

1.6%

2

423

1.0%

411

1.0%

44450

693

1.6%

5978

13.4%

430

1.0%

31697

71.3%

450

1.0%

a.
b.
c.

Superinfection briefly written. It is the CAT yield coming from the cells that were superinfected by HSVl.
Unsuperinfection. That is the CAT yield coming from the cells that were not superinfected by HSVl.
The percentage compared with superinfected wt VPS CAT values.

The condition of this experiment was same as table 5. Two times CAT assays have been done.
According to this table, I get the average percentage of Mut.1 CAT yield 12.4% (S.D. is 1.4%) and
Mut.2 CAT yield 74.0% (S.D. is 3.8%) compared with wt VP5 that is considered as 100% CAT yield
(see Fig.15).
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Fig.16 Competition binding assay III. Lanes 1, 4
and 7 without NE, all other lanes with NE. 120-fold
molar excess of SPl was added to Lanes3, 6 and 9.
All the complexes C were inhibited by the SPl
oligonucleotide.

CHAPTER V
DISCUSSION
The results of my research in the past two and half years under the guidence of
Dr. Robert L. Millette has shed some light onto the molecular mechanisms of how the
transcription of the Herpes Simplex Virus Type 1 (HSV 1) VP5 gene is regulated in
human Hela cells. Based on my data and those obtained previously in Dr. Millette's
laboratory, it has become clear now that the cis regulatory element, Leaky-late gene
binding site (LBS), located within the first 164 base pairs (bp) promoter region of the
VP5 gene is required for the maximal transcriptional activation of the VP5 gene in Hela
cells. In addition, the LBS element has been shown to bind a cellular trans-acting factor
in a sequence specific manner. Furthermore, seven nucleotides out of twelve in the LBS
region, situated near 5' end and 3' end of LBS, are critical for both the binding of the
transcription factor and overall promoter activity of the 164 bp fragment. Evidence from
both biochemical and immunological studies of my experiments and previous
observation from this laboratory almost unequivocally indicated that the trans-acting
factor interacting with the LBS cis element is very similar, if not identical, to the
previously identified transcription factor, Ying-Yang 1 (YY 1) (36). Interestingly,
depending on the flanking sequences of the LBS element, the binding of YY 1 onto LBS
could play either positive or negative role in regulating VP5 gene expression.
The above results opened a whole new avenue for more detailed characterization
of VP5 transcriptional regulation in Hela cells. Specifically, one can address the
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following questions: (1) Is YY 1 the only protein that binds to the LBS site or there are
other nuclear proteins binding to LBS? There have been many examples that one DNA
binding site could be occupied by various proteins at different developmental stages or
under different physiological conditions (30). In addition, recent experiments by L.
Mills have shown that, in the glycoprotein D promoter, YY 1 and factor SPl may
compete for binding to overlapping sites. (2) Does YY 1 interact with any other
transcription factors in regulating VPS promoter? For example, it is noticed there is a
highly conserved Spl site located downstream of the LBS and previous experiments
have shown that Spl site is required for the 164 bp VPS promoter activity (36). Studies
from Shenk's group have indicated that Spl and YY 1 can interact direcly with each
other to exert synergistic regulation of the OST-fusion proteins gene (29). Thus, it is
conceivable that YY 1 can also interact with Spl on VPS promoter to regulate its
expression. (3) Is this binding protein the same YY 1 as previouly identified by Shi and
Shenk (39,) or is it a related isofrom? (4) Is the expression or activity of YYl regulated
by herpes simplex virus infection? The significance and feasibility of addressing these
questions as well as the analyses of the experimental results are discussed in details as
follows.

A. The LBS site activates VP5 gene expression by binding to a cellular
factor(s).
Previous studies have shown that a 9 bp element, LBS, within the 164 bp
promoter region in the VPS gene is required for the full activity of the 164 bp promoter.
Even though the sequences of the LBS element showed high degree of similarity to
those of the previously characterized transcription factor YYl and Spl, there was little
known about the trans-acting factors that interact with LBS. In order to identify and
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characterize the putative transcription factors that interact with LBS, gel mobility shift
assays were first carried out. When the Hela nuclear extract was incubated with a 164
bp fragment containing the LBS site, three DNA-proteins complexes could be detected
(A, B and C). Deletion of the LBS from the same fragment completely abolished the
formation of A and B DNA-protein complexes, which stronly implicate the role of these
DNA-protein complexes in regulating VP5 transcription (mutation 13/6, Fig.7). When
the LBS sequences were ligated back into the same fragment, the formation of the A and
B DNA-protein complexes were fully restored. Therefore, the binding of these nuclear
proteins to the VP5 promoter is specific for the presence of LBS. Interestingly, point
mutations at certain loci of the LBS element specifically abolished the formation of the
A and B complexes, while the binding of band C was unaffected (Fig. 14). Transient
expression assays showed that these point mutations decreased the promoter activity
significantly (Fig.15). These results indicated that complexes A and B were recognized
by different cellular factors then complex C was, which suggests that they are different
factors; (2) the forming of complexes A and B are functionally required for the
expression of VP5.

B. The protein that forms the complexes A and B with the LBS element
is closely related, if not identical, to the YYl transcription factor while
the factor that forms the complex C may be related to Spl transcription
factor.
Since the first 164 bp of VP5 promoter contains a YY 1 like element and Sp 1 like
element, a series of experiments were carried out to determine whether the proteins that
form the complexes A, B and Care related to YYl or Spl. By a number of criteria
(binding competition, partial proteolysis, and monoclonal antibcxly assays), the proteins
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that forms complexes A and B appear to be closely related to, if not identical to, the
previously identified transcription factor YY 1 (36). An oligonucleotide containing the
consensus binding site of SPl could efficiently compete away the complex C from w.t.
VP5 probe, indicating this cellular factor may be related to SPl factor (Fig.16). The
fact that endogenous SPl can bind to the downstream consensus SPl site raises the
question of whether the endogenous SPl is also involved in the regulation of VP5
transcription. Especially, SPl and YY 1 have been shown to co-regulate a number of
genes (30), it is possible that these factors interact with each other on the VP5 promoter
in the activation of VP5 transcription. To test the possibility, the first step would be to
determine whether mutation of the downstream SPl site will affect the VP5 promoter
activity. If SPl factor is involved in the regulation, then the following experiments
could be proposed to determine whether YY 1 and SPl function synergistically by
directly interacting with each other. (1) One can perform immuno co-precipitation with
antibody agains either the endogenous SPl or YY 1 to detect the putative in vivo
SPl/YY 1 complex. (2) One can also carry out co-transfection assays to over-express
either YY 1 and VP5/CA T, SPl and VP5 or YY l/SP1/VP5. If YY 1 and SPl function
synergistically, overexpression of both YY 1 and SPl should lead to higher expression
of CAT from the VP5 164 bp promoter than any single of these. Since the endogenous
SPl activity in Hela cells is quite high overexpression of the exogenous SPl may not
show any further activaiton. This potential problem could solved by using a Drosophila
Melanogaster cell line which has almost no detectable SPl activity.

C. Depending on the flanking sequences, the binding of YYl to the YYl
site in the VPS promoter could result in either a positive or negative
control of VPS transcription.
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When the YYl site with three additional base pairs at the 5' end and six at the 3'
end of was added to the YY 1 deleted VP5 promoter, the promoter activity was
decreased by five fold compared to the wild type promoter (Fig.9). Supprisingly, the
level of binding of YY 1 to the added YY 1 site was identical to that of wild type. The
YY 1 factor, however, has been shown to have dual regulatory property: it could either
activate or suppress transcription of certain genes (53). Even though the additional nine
base pairs added to either 3' or 5' end of YYl site did not change the binding efficiency,
it could very well change the three demensional relationships of the YY 1 protein sitting
on VP5 promoter to other VP5 transcription factors including SPl. This is especially
important in light of recent results showing that YYl can bend DNA to effect a positive
or negtive control. In order to fully understand VP5 transcriptional regulation the above
possibility should be further explored by future experiments. The same experiments
described as above can be carried out to determine whether YY 1 and SPl still interact
with each other at presence of the same additional base pairs. Furthermore, the possible
alterations of either YY 1 or SPl domanis involved in the interacting can be studied by
various biochemical techniques, e.g. chemical cross linking studies . The interacting
domains can then be studied in greater detail by site directed mutagenesis. Hopefully, in
the long run, this study will provide scientific bases for clinical application. One
possibility is one might be able to disrupt the functional interaction of YY 1 and SPl by
introducing either YYl or SPl interacting domain only to compote with the endogenous
boll oprotein.

D. The nucleotides of YYl site are not equally important for VP5
promoter activity.
At the resolution of gel mobility shift assays, I could not distinguish Mutation 1
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from Mutation 2 with regarding to the efficiency of disrupting binding; the promoter
activities of both mutations varied profoundly (Fig. 15). Mutation 1 reduced CAT
expression to 12.5% of wild type whereas Mutation 2 only to 73.5%. One possible
explanation to this puzzling phenomenum is that there is still some residual binding of
YY 1 to Mutant 2 YY 1 site which is below the detectable level of gel mobility shift
assays. This explanation could be tested by more sensitive titration competition assays
where the wild type YY 1 site will be used as the probed and various amounts of Mutant
1 and Mutant 2YY1 site will be used as the competitors. It is worth noting, however,
that other laboratories have also found that nucleotides at the 5' end of YY 1 site appear
to be more important than those near the 3' end.

E.

Additional future experiments for completely understanding the

mechanism of how HSVl is regulated.
It is still not completely clear whether the YYl is the only factor interacting with
the VP5 YY 1 site or whether the YY 1 we detected in Hela cells is exactly the same as
previously characterized one. To sort this out, one can perform methylation interference
assay to determine whether the contact points of YY 1 on VP5 match previous results.
And it is also worth searching for different isoforms of YY 1 in Hela cells using either
low stringecy screening or PCR technique.
It would be interesting to study whether the expression of the endogenous YY 1
or SPl is regulated at the infection of HSV 1. Since it is clear that YY 1 and SPl are
involved in regulating a number of cellular genes, to understand the interplay of HSVl
and the endogenous YYl and SPl may help to understand not only how HSVl
infection may indirectly manifest its pathogenesis but also how the infection change the
host cell metabolism.

REFERENCES
1. Bauknecht, T,.P. Angel et al. 1992. Identification of negative regulatory
domain in the human papillomavirus type 18 promoter: interaction with the
transcriptional repressor YYl. The EMBO Journal 11: 4{X}7-4617.
2. Blair, E. D., and E. K. Wagner. 1986. A single regulatory region modulates
both cis activation and trans activation of the herpes simplex virus VP5 promoter in
transient expression assays in vivo. J. Virol. 60:460-469.
3. Cai, W., and P. A. Schaffer. 1989. Herpes simplex virus type 1 ICPO plays
a critical role in the de novo synthesis of infectious virus following transfection of
viral DNA. J. Virol. 63:4579-4589.
4. Chen, S., L.Mill et al. 1992. Transactivation of Major Capsid Protein Gene of
Herpes Simplex Virus Type 1 Requires a Cellular Transcription Factor. J. Virol.
66:4304-4314.

5. Costa, R. H., K. G. Draper, G. Devi-Rao, R. L. Thompson, and E.
K. Wagner. 1985. Virus-induced modification of the host cell in required for
expression of the bacterial chloramphenicol acetyltransferase gene controlled by a
late herpes simplex virus promoter (VP5). J. Virol. 56: 19-30.
6. DeLuca, N. A., and P. A. Schaffer. 1985. Activation of immediate-early,
early, and late promoters by temperature-sensitive and wild-type forms of herpes
simplex virus type 1 protein ICP4. Mol. Cell. Biol. 5: 1997-2008.
7. Dennis, D., and J. R. Smiley. 1984. Transactivation of a late herpes simplex
virus promoter. Mol. Cell. Biol. 4:544-551.
8. Dignam, D., R. M. Ledowitz, and R.G. Robert. 1983. Accurate
transcription initiation by RNA polymerase II in asoluble extract from isolated
mammalian nuclei. Acids. Res. 11:1475-1489.
9. Dixon, R. A. F., and P. A. Schaffer. 1980. Fine structure mapping and
functional analysis of temperature-sensitive mutants in the gene encoding the herpes
simplex virus type 1 immediate-early protein VPl 75. J. Virol. 6: 189-203.
10. Dretzen, G., M. Bellard, P. Sassone-Corsi, and P. Chambon. 1981.
A reliable method for the recovery of DNA fragments from agarose and acrylamide
gels. Anal. Biochem. 112:295-298.
11. Dulbecco, Rand H. Ginsberg. 1988. Virology. Second edition. N.Y.
12. Everett, R. D. 1984. A detailed analysis of an HSV 1 early promoter: sequences
involved in transcativation by viral immediate-early gene products are not earlygene specific. Nucleic Acids Res. 12:3037-3056.

60

13. Everett, R. D. 1984. Transactivation of transcription by herpes-virus products:
requirements for two HSVl immediate early polypeptides for
maximum
activity. EMBO J. 3:3135-3141.
14. Everett, R. D. 1986. The products of herpes simplex virus type l(HSVl)
immediate-early genes 1,2 and 3 can activate HSVl gene expression in trans. J.
Gen. Virol. 68:2507-2513.
15. Flanagan, W. M., A. G. Papavassiliou, M. Rice, L. B. Hecht, S.
Silverstein, and E. K. Wagner. 1991. Analysis of the herpes simplex virus
type 1 promoter controlling the expression of Ul.38, a true late gene involved in
capsid assembly. J. Virol. 65:769-786.
16. Garner, M. M., and A. Revzin. 1981. A gel electrophoresis method for
quantifying the binding of proteins to specific DNA regions: application to
components of the E. coli lactose operon regulatory system. Nucleic Acids Res.
9:3047-3060.
17. Godowski, P. J., and D. M. Knipe. 1986. transcriptional control of
herpesvirus gene expression: gene functions required for positive and negative
regulation. Proc. Natl. Acad. Sci. USA 83:256-260.
18. Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant
genomes which express chloramphenicol acetyltransferase in
mammalian
cells. Mol. Cell. Biol. 2: 1044-1051.
19. Gualberto, A. et al. 1992. Functional antagonism between YY 1 and the serum
response factor. Mol.Cell. Biol. 12:4209-4214.
20. Harris-Hamilton, E., and S. L. Bachemheimer. 1985. Accumulation of
herpes simplex virus type 1 RNAs of different kinetic classes in the cytoplasm of
infected cells. J. Virol. 53: 144-151.
21. Holland, L., K. Anderson, C. Shipman, Jr., and E. Wagner. 1980.
Viral DNA synthesis is required for the efficient expression of specific HSVl
mRNA species. Virology 101: 10-24.
22. Honess, R. W ., and B. Roizman. 1974. Regulation of herpesvirus
macromolecular synthesis. I. Cascade regulation of the synthesis of three groups
of viral proteins. J. Virol. 14:8-19.
23. Honess, R. W., and B. Roizman. 1975. Regulation of herpesvirus
macromolecular synthesis: sequential transition of polypeptide synthesis requires
functional viral polypeptides. Proc. Natl. Acad. Sci. USA 72: 1276-1280.
24. Hou, Y. 1990. Molecular Virology. B.J.
25. Johnson, P. A., and R. D. Everett. 1986. The control of herpes simplex
virus type 1 late gene transcription: A 'TATA-box'/cap site region is sufficient for

61
fully efficient regulated activity. Nucleic Acids Res. 14:8247-8264.
26. Jones, P., and B. Roizman. 1979. Regulation of herpesvirus macromolecular
synthesis. VIII. The transcription program consists of three
phases during
the cytoplasm
which both extent of transcription and accumulation of RNA in
are regulated. J. Virol. 31:299-314.
27. Kuwahara, M., and D. Sigman. 1987. Footprinting DNA-protein complexes
in situ following gel retardation assays using 1,10-phenanthroline- copper ion:
Escherichia coli RNA polymeraselac promoter complexes. Biochemistry 26:72347238.
28. Kwong, A. D., and N. Frenkel. 1988. Herpes simplex virus type-1 infected
cells contain a function(s) that stabilizes both host and viral mRNAs.
Proc.
Natl. Acad. Sci. USA 84: 1926-1930.
29. Lee, T., Y. Shi and R.J. Schwartz. 1992. Displacement of BrdUrd-induced
YY 1 by serum response factor activates skeletal a-actin transcription in
embryonic myoblaste. Proc. Natl. Acad. Sci. USA. 89:9814-9818.
30. Lee, J.,K.M. Galvin and Y. Shi. 1993. Evidence for physical interaction
between the zinc-finger transcription factors YYl and Spl. Pro. Natl. Acad.Sci.
USA 90:6145-6149.
31. Maniatis, T., J. Sambrook, and E.G. Fritsch. 1989. Molecular cloning,
a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring
Harbor, N.Y.
32. McCarthy, A. M., L. McMahan, and P. A. Schaffer. 1989. Herpes
simplex virus type 1 ICP27 deletion mutants exhibit altered patterns of
transcription and are DNA deficient. J. Virol. 63: 18-27.
33. McGeogh, D. J., M. A. Dalrymple, A. J. Davison, A. Dolan, M. C.
Frame, D. McNab, L. J. Perry, J. E. Scott, and P. Taylor.
1988.
The complete sequence of the long unique region in the genome of herpes simplex
virus type 1. J. Gen. Virol. 69: 1531-1574.
34. McGeogh, D. J., A. Golan, S. Donald, and F. J. Rixon. 1985.
Sequence determination and genetic content of the short unique region in the
genome of herpes simplex virus type 1. J. Mol. Biol. 181: 1-13.
35. Millette, R. L., and R. Klaiber. 1980. Gene expression of herpes simplex
virus. II. UV radiological analysis of viral transcription units. J. Virol. 34:604614.
36. Mills, L.and R. L, Millette. 1994. YY 1 is the Cellular Factor Previously to
Bind the Certain Leaky-late Genes of Herpes Simplex Virus Type 1. J. Virol. ()6:
1234-1240.
37. Natesan, S. and M.Z. Gilman. 1993. DNA bending and orientation-

62
dependent function of YYl in the c-fos promoter. Gen Devel. 7:2497-250').
38. Nordeen, S. K., P. P. Green III, and D. M. Fowlkes. 1987. A rapid,
sensitive and inexpensive assay for chloramphenicol acetyltransferase. DNA
6:173-178.
39. Park, K. and M.L. Atchison. 1991. Isolation of a candidate
repressor/activator, NF-El (YY-1, b ), that binds to theimmunoglobulin K 3'
enhencer and the immunoglobulin heavy-chain µEl site. Proc. Natl. Acad. Sci
USA 88 :9804-9808

40. Pedersen, M. M., S. Taley-Brown, and R. L. Millette. 1981. Gene
expression of herpes simplex virus. III. Effect of arabinosyladenine on viral
polypeptide synthesis. J. Virol. 38:712-719

41. Perry, L. J., F. J. Rixon, R. D. Everett, M. C. Frame, and D. J.
McGeogh. 1986. Characterization of the IEl 10 gene of herpes simplex virus
type 1. J. Gen. Virol. 67:2356-2380.
42. Preston, C. M. 1979. Abnormal properties of an immediate-early polypeptide
in cells infected with the herpes simplex virus mutant defective in virion-associated
shutoff. J. Virol. 46:498-512.
43. Read, G.S. and N. Frenkel. 1983. Herpes simplex viru smutant defective in
virion-associated shutoff. J. Virol. 46:498-512.

44. Rice, S. A., and D. M. Knipe. 1988. Gene-specific transactivation of herpes
simplex virus 1 alpha protein ICP27. J. Virol. 62:3814-3823.
45. Rice, S. A., and D. M. Knipe. 1990. Genetic evidence for two distinct
transactivation functions of the herpes simplex virus a protein ICP27. J. Virol.
64: 1704-1715.
46. Riggs, K.J. and S. Saleque, et al. 1993. Yin-Yang-1 activates the c-myc
promoter. Mol. Cell. Biol. 13:7487-7495.
47. Roizman, B., and A. E. sears. 1990. Herpes simplex viruses and their
replication, p. 1795-1841. In B. Fields and D. Knipe (ed.), Fields virology, 2nd
ed. Raven Press, New York.

48. Roizman, B., R. J. Whitley and C.Lopez. 1993. The herpesviruses.
Second edition. 1-8.
49. Rouse,B. T. and C. Lopez. 1984 Immunobiology of Herpes Simplex Virus
Infection. Boca Raton, Florida.
50. Sacks, W. R., C. C. Greene, D. P. Aschman, and P. A. Schaffer.
1985. Herpes simplex virus ICP27 is an essential regulatory protein. J. Virol.
55: 796-805.

63
51. Sekulovieh, R. E., K. teary, and R. M. Sandri-Goldin. 1988. the
herpes simplex virus type 1 protein ICP27 can act as a trans-repressor or a transactivator in combination with ICP4 and ICPO. J. Virpl. 62:4510-4522.
52. Seto, E., B.Lewls and T. Shenk. 1993. Interaction Between Transcription
Factors Sp 1 and YY 1. Nature 365: 462-464.
53. Seto, E. Y. Shi and T. Shenk. 1991. YY 1 is an initiator sequence-binding
protein that directs and activates transcription in vitro. Nature. 354: 241-248.

54. Shelton, L. S. G., M. N. Pensiero, and F. J. Jenkins. 1990.
Identification and characterization of the herpes simplex virus type 1 protein
encoded by the Ul.37 open reading frame. J. Virol. 64:6101-6109
54. Shi, Y., E. Seto, L. S. Chang, and T. Shenk. 1991. Transcriptional
repression by YYl, a human GLI-Kruppel-related protein, and relief of repression
by adenovirus ElA protein. Cell. 67:377-388.
55. Shi, Y. and E. Seto et al. 1991. Transcriptional repression by YY 1, a human
GLI-Kruppel-Related protein and relief of repression by adenovirus ElA protein.
Cell. 67:377-388.

56. Shrivastava,A. et al. 1993. Inhibition of transcriptional regulator Yin-Yang-1
by association with c-myc. Science. 262: 1889-1993.
57. Smith, I. L., M. A. Hardwicke, and M. Sandri-Goldin. 1992. Evidence
that the herpes simplex virus immediate rarly protein ICP27 acts posttranscriptionally during infection to regulate gene expression. Virology 186:74-86.
58. Su, L., and D. M. Knipe. 1989. Herpes simplex virus a protein ICP27 can
inhibit or augment viral gene transactivation. Virology 170:496-504.
59. Wagner, E. K. 1985 Individual HSV transcipts: Characterization of specific
genes, p.45-104. In B. Roizman. Herpesviruses, vol. 3. Plenum Press, New
York.

60. Watson, R. J., and J. B. Clements. 1978. Characterization of transcriptiontype 1. Vrology
deficient temperature-sensitive mutants of herpes simplex virus
91:364-379.
61. Weinheimer, S., and S. L. McKnight. 1987. Transcriptional and posttranscriptional controls establish the cascade of herpes simplex virus protein
synthesis. J. Mol. Biol. 195:819-8.
62. Zhang, Y. F., G. B. Devi-Rao, M. Rice, R. M. Sandri-Goldin, and
E. K. Wagner. 1987. The effect of elevated levels of herpes simplex virus agene products on the expression of model early and late genes in vivo. Virology
157:99-106.

THE FUNCTIONS OF YYl
I.

Repressor in:
1. Adeno-associated virus (AA V) PS promoter

2. Immunoglobulin (lg) k 3' enhancer
3. c-fos promoter
4. Human papilloma virus-18 promoter
S. Skeletal a-actin promoter
6. long terminal repeat of Moloney leukemia virus

II.

Activator in:
1. c-myc promoter

2. lgH intronic enhencer
3. Promoters of ribosomal proteins L30 and L32

III.

Initiator at nucleotide position + 1 in the AAV PS promoter

